Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

Eileen W Stalman,Nicoline F Post,Zoé L E Van Kempen,Mark Löwenberg,Dirk Jan Hijnen,Frederique J Bemelman,Niels J M Verstegen,Diane Van Der Woude,Geert R D’haens ,Luuk Wieske,W Ludo Van Der Pol ,Gertjan Wolbink ,Jelle De Wit,Maurice Steenhuis,Marc Hilhorst ,Anja Ten Brinke,R Bart Takkenberg ,Esther Brusse,Corine R G Schreurs,Adriaan Volkers ,Alexandre E Voskuyl ,Theo Rispens,Phyllis I Spuls ,Angela L Bosma ,Lotte Van Ouwerkerk,Cornelia F Allaart ,Laura Boekel,Y K Onno Teng ,Taco W Kuijpers ,Koos P J Van Dam,Sofie Keijzer,H Stephan Goedee ,Marcel W Bekkenk ,Arend Boogaard,Pieter A Van Doorn ,S Marieke Van Ham ,Pieter Van Paassen,Jan Verschuuren ,Joep Killestein,Olvi Cristianawati,Adája E Baars ,Bo Broens,Yosta Vegting,Sander W Tas ,Agner Parra Sanchez,Abraham Rutgers,Jim Keijser ,Koos Zwinderman ,Laura Kummer ,Matthias Busch ,Anneke J Van Der Kooi ,Cécile A C M Van ,Joost Raaphorst,Barbara Hórvath ,Karina De Leeuw,Annelie H Musters,Papay B P Jallah,Annabel M Ruiter ,Filip Eftimov

doi:10.1136/ard-2022-222904

Abstract

ObjectivesTo compare the cumulative incidence and disease severity of reported SARS-CoV-2 omicron breakthrough infections between patients with immune-mediated inflammatory diseases (IMID) on immunosuppressants and controls, and to investigate determinants for...

Full Text